Clinical Trial Update: Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Cetuximab/FOLFIRI with or without Oxaliplatin, and FOLFOXIRI with or without Bevacizumab for neoadjuvant treatment of non-resectable co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Liver Metastases

Drugs mentioned

• Bevacizumab (bevacizumab)
• Cetuximab (cetuximab)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• FOLFOXIRI (folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin, irinotecan)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Technische Universität Dresden | Conditions: Colorectal Cancer | Phase 2 | Status: UNKNOWN